Drug analysis: Erbitux

  • ID: 4462143
  • Drug Pipelines
  • 34 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA) is a chimeric monoclonal antibody (MAb) that binds to the extracellular domain of epidermal growth factor receptor (EGFR). The receptor is involved in the regulation of cell growth, proliferation, and differentiation. Erbitux is composed of the Fv regions of a murine EGFR MAb-specific for the N-terminal portion of human EGFR with human immunoglobulin G1 heavy and k-light chain constant regions. Binding of Erbitux to EGFR interferes with ligand-mediated activation of the receptor’s intracellular tyrosine kinase activity and inhibits the EGFR-mediated signaling. This results in the inhibition of cell growth, induction of apoptosis, decreased matrix metalloprotease secretion, and reduced vascular endothelial growth factor production. Erbitux may also induce the activation of the immune system through antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
Erbitux: Colorectal cancer (CRC)
Erbitux: Head and neck cancer

List of Figures
Figure 1: Erbitux for colorectal cancer - SWOT analysis
Figure 2: Drug assessment summary of Erbitux for colorectal cancer
Figure 3: Drug assessment summary of Erbitux for colorectal cancer
Figure 4: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
Figure 5: Erbitux for head and neck cancer - SWOT analysis
Figure 6: Drug assessment summary of Erbitux for SCCHN
Figure 7: Drug assessment summary of Erbitux for SCCHN
Figure 8: Erbitux sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables
Table 1: Erbitux drug profile
Table 2: Overview of major approvals for Erbitux in colorectal cancer
Table 3: Erbitux Phase III data in colorectal cancer
Table 4: Erbitux Phase III data in colorectal cancer
Table 5: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 6: Patients treated with Erbitux across the US, Japan, and five major EU markets, by country, 2016-25
Table 7: Erbitux drug profile
Table 8: Erbitux pivotal trial data in head and neck cancer
Table 9: Erbitux sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 10: Erbitux patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll